CPRX קפיטליזציה חשבונאית Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals (CPRX) ensures the uninterrupted supply of orphan drugs through proven express delivery channels, which maintains profits at 1.01. The stock price action visualized on GURU.Markets confirms the success of the Catalyst Pharmaceuticals strategy, which relies on exclusive rights in the therapy of rare pathologies. Meanwhile, the business fully outsources production to external GMP-certified plants, minimizing its own operating expenses.

Market capitalization measures the market value of all company shares at the close of the trading session, allowing for the real-time tracking of business valuation dynamics between quarterly reports. An analysis of the balance sheet capitalization level confirms the financial stability of Catalyst Pharmaceuticals (CPRX), whose value is supported by its monopoly position in the US market for specialized neuromuscular drugs.